



EuroBleedNet :

New Therapies for Sickle Disease Patients

Malika BENKERROU, Valentine BROUSSE and team

Director of the Reference labelled Constitutive Red blood cells



Inserm

UMR1163

and Eythropoieisis disorders center at Robert-Debré University Hospital APHP and MCGRE labelled network ERN-EuroBloodNet subnetwork: Red Blood Cell Paris-France 31 of January 2022





Diseases (ERN EuroBloodNet)

Co-funded by





Investigator Post label registry (Addmedica)



for rare or low prevalence complex diseases





- **1.** Introduction to SCD
- **2.** Disease modifying therapies
- **3.** Curative Approach
- **4.** Comprehensive SCD center
- **5.** Take home messages
- 6. Discussion



for rare or low prevalence complex diseases





1. Introduction to SCD new therapies

1.Introduction to SCD


2.Targets



for rare or low prevalence complex diseases







uropean ference etwork

Network

Hematological

for rare or low prevalence complex diseases

- Single nucleotide mutation: β globin 6th codon - Transversion $A \rightarrow T$ $-6^{\text{th}}AA \text{ Glu} \rightarrow \text{Val}$: Hb $A \rightarrow S$: = HbS Polymerise upon deoxygenation -Symptoms Chronic hemolytic anemia Vaso-occlusion Functionnal Asplenia : high susceptibility

to encapsulated bacterial infections

-Diagnosis:

-Adult: Hb electrophoresis

-newborn: isoelectric focalisation HPLC or MS






- For example: Pain in sickle cell disease (Platt OS et al NEJM 1991)
- 2412 patients with homozygous SCD (Inclusions from 1979 to1986)
- No neonatal screening nor implemented care after neonatal screening
- Patients with pain symptoms/year
 - No pain : 39%
 - >6 épisods : 1%
 - 3 à 10 episods
- : 5.2% responsibles for 32.9% of pain events
- No individual prognostic factor



for rare or low prevalence complex diseases

Network Hematological Diseases (ERN EuroBloodNet)



(Stuart MJ, Nagel RL. Lancet 2004) Response to stress: oxydative, inflammatory, Hypoxia-reperfusion: →Driven by microcirculation partners and tissue polymorphisms Webinars

Topic on Focus

FuroBlaadNet

- Without care or in low income countries : very severe disease
 - Early and unpredictable Mortality
 - 50 à 80% before 5 years of age (peak between 6 to 18 mo)
 - 50% Infectious (2/3pneumoccocal)
 - 45% Acute Anaemia (mainly ASS)



• **Prevention:** Drastic decrease of mortality (and morbidity) before 5 years of age

between 0 and 5% (Gill FM Blood 1995; Lee BMJ, 1995, Telfer Hematologica 2007, Quinn CT Blood 2010, Bernaudin F Blood 2011, Couque N BJH 2016)

- Neonatal screening, organised health and social network
 - Peni V, anti-pneumococcal, meningococcal vaccines, parental and referent adult education (Fever, Pain, Pallor, treatments), folic acid, support to ttt compliance, TCD..., regular outpatient and annual review)




for rare or low prevalence complex diseases

Network Hematological Diseases (ERN EuroBloodNet) • Early Intervention whenever needed: TP, Hydroxycarbamide, HSCT, other disease modifying or curative therapies.



Introduction to SCD new therapies : TARGETS (1)






MORTALITY IN SICKLE CELL DISEASE

Life Expectancy and Risk Factors for Early Death

Orah S. Platt, M.D., Donald J. Brambilla, Ph.D., Wendell F. Rosse, M.D., Paul F. Milner, M.D., Oswaldo Castro, M.D., Martin H. Steinberg, M.D., and Panpit P. Klug, M.D.

(N Engl J Med 1994;330:1639-44.)



Hematological Diseases (ERN EuroBloodNet) •CSSCD: 2542 SS patients included between1978 and 1988

•No neonatal screening nor implemented care after neonatal screening

•Life expectancy: 42 y for men and 48 y for women, improved when ↑ **HbF**



New SCD therapies :



2.Disease modifying therapies

- 1. Antisickling agents
- 2. Antidhesion therapies
- 3. Optimising oxygenation.
- 4. Increasing Hb F expression
 - 5. Substitutive therapy
 - 6. Empowerment
 - 7. Prevention





for rare or low prevalence complex diseases



- GBT-440 (VoxelatorR) maintains HbS in oxyform by binding covalently alpha genes
 - Lowers polymerisation
 - Increase in Hb and decrease in hemolysis parameters
 - Hopekids II trial: 2-12 y kids with conditionnal TCD/placebo



for rare or low prevalence complex diseases





- Pyruvate Kinase Activator (FT-4202 Etavopivat)
 - Decreases 2-3DPG And Increases ATP

- Increases Hb Affinity for O2 (less deoxy HbS) and improves Red blood cell repair
 - SCD trials showed
 - increased Hb
 - an decreased Hemolysis
 - Hibiscus phase II/III trials ongoing for kids with 2 or more VOC drug/placebo





2. anti-adhesion

• Anti p-selectin

DOI: 10.1002/ajh.25308

RESEARCH ARTICLE

Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis

Abdullah Kutlar¹ | Julie Kanter² | Darla K. Liles³ | Ofelia A. Alvarez⁴ | Rodolfo D. Cançado⁵ | João R. Friedrisch⁶ | Jennifer M. Knight-Madden⁷ | Andreas Bruederle⁸ | Michael Shi⁹ | Zewen Zhu⁹ | Kenneth I. Ataga¹⁰

- -40% reduction in VOC rate
- -2 IVLx2/month then once a month
- -Do not need every day compliance
- -Team and adult centres experience: Interesting in patients compliant to HU remaining symptomatic No evidence of effect for those needing HU and not taking it



for rare or low prevalence complex diseases

iropean







Am J Hematol. 2019;94:55-61.

- Identifying new risk factors with adapted statistical methods
 - Longitudinal biological and clinical data on newborn cohort
 - for macrovascular disease
 - Risk factors : ENT and bronchial obstruction, reticulocyte count
 - Protective factor : Increase of HbF
 - Easy factors to target

bih research paper

British Journal of Haematology, 2016, 172, 966-977

Clinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study Sommet J et al

Variability of Prognostic Results Based on Biological Parameters in Sickle Cell Disease Cohort Studies in Children: What Should Clinicians Know? Children 2021, 8, 143. https://doi.org/10.3390/children8020143 Sommet J et al



European Reference Network for rare or low prevalence complex diseases



4.Re-expressing HbF: Gene therapy (Inhibiting BCL11A)

N ENGL J MED 384:3 NEIM.ORG JANUARY 21, 2021




CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β -Thalassemia

H. Frangoul, D. Altshuler, M.D. Cappellini, Y.-S. Chen, J. Domm, B.K. Eustace, J. Foell, J. de la Fuente, S. Grupp, R. Handgretinger, T.W. Ho, A. Kattamis, A. Kernytsky, J. Lekstrom-Himes, A.M. Li, F. Locatelli, M.Y. Mapara, M. de Montalembert, D. Rondelli, A. Sharma, S. Sheth, S. Soni, M.H. Steinberg, D. Wall, A. Yen, and S. Corbacioglu

1 patient with Beta0/beta+ thal TD and 1 with SCD with frequent VOC Pre apheresis TP Apheresis x3 of mobilized STC Myeloablative conditionning regimen SCD patient is free of symptoms with more than a year follow-up HbF rose from 9.1% to 43,2% HbS decrease from 74% to 52.3%, 100% of F cell

BCL11A is silencing gamma globin genes during development: HbF — HbA or HbS silencing specifically its expression activates gamma globin gene again




Diseases (ERN EuroBloodNet)




Old dog New tricks (1-2-4 VR) Hydroxycarbamide




- Ribonucleotid reductase inhibitor
- Beneficial pleiotropic effects





after 6mo of HC



1- ↑Σ HbF

- $2 \downarrow$ Production adherent cells PMN, Reticulocytes, Platelets
- $3-\downarrow$ adhesion molecules on Reticulocytes, PMN
 - \downarrow Endothelin 1 (vasoconstrictor)
 - $-\downarrow$ Endothelial injuries
- 4- Macrocytosis:
 - - \uparrow red blood cell hydratation: \downarrow [HbS]
 - -↑deformability
 - -↓Haemolysis
- 5- \uparrow NO (vasodilation)



Ware RE, Blood 2010

for rare or low prevalence complex diseases


Network lematoloaical Diseases (ERN EuroBloodNet) **Terribly under utilized, 40% or less patients**

Topic on Focus EuroBleedNet ? with VOC or anemia < 7g/dl are treated with HC Couque N BJH 2016)



Topic on Focus

EuroBleedNet ?



Survival curve with Ferritinemia<1000µg/l Continous manual exchange=Erythrapheresis B Koelh et al TRANSFUSION 2016;56;1121-1128

•Monthly National neuroradiology expertise meeting Thousands images and charts review since 1998 •Coordinated by our neuro-radiologists and our team •Preventing erroneous TP and safely resuming TP



Exchange transfusion therapy without iron overload TCD and ARM normalisation Safe switch to HC after 5 y Webinars for rare or low prevalence

Network Iematological Diseases (ERN EuroBloodNet)

complex diseases



6. Support and empowerment



- Psychological (support, self esteem, stress control)
- Mediation
- Treatment adherence, educated health-care provider, parent and patient expert
 - oral medications work if taken
 - only for personal goals that change with time (play with friends, football, "white eye"....)
 - Had to be encouraged
 - Discouragement is acceptable
 - Therapy has to be quickly at the best dosage
- Adolescent and young adult support through a smartphone application connected to a dedicated nurse platform (Applidrep)



complex diseases Network Hematological Diseases (ERN EuroBloodNet)





• Prevention:

bjh research paper

Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines British Journal of Haematology, 2016, 173, 927–937

Couque N et al



for rare or low prevalence complex diseases



New SCD therapies :



3. "Curative" therapies 1.Bone marrow transplant 2. Gene therapy



for rare or low prevalence complex diseases



Curative Therapies(1) « Allogenic Bone Marrow transplant »





Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease

Eliane Gluckman¹

Hematology 2013

ASH 370-376

¹Eurocord, Hospital Saint Louis, Assistance Publique–Hôpitaux de Paris, Université Paris-Diderot, Paris, France

- HLA Identical donor
- Myeloablative conditionning regimen (ALS, Busulfan Cyclophosphamide, IS regimen 1Y post transplant
- >1000 in the world
 - 25 to 30% of paediatric patients have a matched donor
 - Mortality 4 to 5%
 - Chronic morbidity (cGVH) 12.6%,
 - Toxicity to be decreased

Our department coordinates an international Multi-professional consultation meeting / 2 months

- Consensus indications (PNDS et NIH 2010):



-Severe forms no responding to HC or confirmed cerebrovascular damage

for rare or low prevalence complex diseases



Curative Therapies(2) « Allogenic Bone Marrow transplant »



The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLAmatched sibling donors: A prospective, single-center, observational study

Robert Sheppard Nickel^{a,b,*}, Willy A. Flegel^c, Sharon D. Adams^c, Jeanne E. Hendrickson^d, Hua Liang^e, John F. Tisdale^f, Matthew M. Hsieh^f EClinicalMedicine 24 (2020) 100432

- HLA Identical sibling
- Non myeloablative Conditionning Regimen (Alemtuzumab 5days, TBI 3GY, Cy 100mg/kg, sirolimus 1 year at least
- ≈10% rejection in the first year, partial chimerism..... Long term outcomes?





Curative Therapies(3) « Allogenic Bone Marrow transplant »

- HLA Haplo-Identical donor
- Myeloablative Conditionning Regimen



for rare or low prevalence complex diseases



New curative SCD therapies: Gene-Therapy



Long-term outcomes of lentiviral gene therapy for the β -hemoglobinopathies: the HGB-205 trial

Elisa Magrin^{12,26}, Michaela Semeraro^{3,4,26}, Nicolas Hebert^{3,5,6,26}, Laure Joseph¹, Alessandra Magnani^{1,2}, Anne Chalumeau⁷, Aurélie Gabrion^{3,1,2}, Cécile Roudaut^{1,2}, Jouda Marouene³, Francois Lefrere¹, Jean-Sebastien Diana^{3,1}, Adeline Denis⁷, Bénédicte Neven⁸, Isabelle Funck-Brentano⁸, Olivier Negre^{9,10,27}, Sylvain Renolleau^{3,11}, Valentine Brousse^{3,12}, Laurent Kiger⁵, Fabien Touzot^{1,2}, Catherine Poirot^{11,34}, Philippe Bourget¹⁵, Wassim El Nemer^{3,16}, Stéphane Blanche⁸, Jean-Marc Tréluyer^{3,4}, Mohammed Asmal^{10,27}, Courtney Walls³⁰, Yves Beuzard^{5,9}, Manfred Schmidt¹⁷, Salima Hacein-Bey-Abina^{1,2}, Vahid Asnafi¹⁸, Isabelle Guichard¹⁹, Maryline Poirée²⁰, Fabrice Monpoux²¹, Philippe Touraine²², Chantal Brouzes²³, Mariane de Montalembert¹⁶, Emmanuel Payen^{3,9}, Emmanuelle Six^{3,7}, Jean-Antoine Ribeil^{12,30,27}, Annarita Miccio^{3,28}, Pablo Bartolucci^{5,6,28}, Philippe Leboulch^{3,9,24,28,22} and Marina Cavazzana^{3,4,25,28,22}

-3 SCD with VOC under HU and TP, no HLA identical donor

-bone marrow harvest with CD34+ purification

-Cultivated in presence of lentiviral vector with modified Beta globin gene insulated targeted to beta globin locus

- -Myeloablation with Busulfan followed by infusion of transfected STC 10 days after
- -40 to 50% expression of the transgene
- -2/3 patients cured with median follow-up of 4.5 y



Network

Hematological Diseases (ERN EuroBloodNet)



NATURE MEDICINE | VOL 28 | JANUARY 2022 | 81-88



4.Comprehensive SCD centers Mandatory WHY???




for rare or low prevalence complex diseases



Comprehensive patient approach Network





From research to care



Better disease control,

Optimize prevention and cure with known tools Research for new disease modifying drugs Access to international trials New statistical tools for defining early risk factors (ie ENT and bronchial obstruction)J Sommet BJH 2016)

Real time evaluation NEODREP Regional Monthly meeting on paediatric "complex situations" Have fun, living well with sickle cell disease Therapeutic education *EDUDREP*, *JEUDREP*, *Applidrep*

progressive empowerment toward adulthood
 Life project (mediation) MEDIADREP
 Pain control (PCA)

J





Stuart MJ, Nagel RL. Lancet 2004

for rare or low prevalence complex diseases



Medical issues of the diagnostic announcement:



Building the therapeutic alliance for life


















for rare or low prevalence complex diseases



- **1.** Collaboration between all health care providers, parents, children, patients:
- 2. Advocacy for referral centres and networking
- **3.** Huge progresses in the past five years
- 4. Tailored therapy with combination of approaches following need of patient for quality of life



for rare or low prevalence complex diseases



Sickle Cell Disease National Référence Center, Robert-Debré University Hospital, Paris France

- •André Baruchel et Jean-Hugues Dalles (MD-PHD)
- •Berengère Koelh, MD, PHD,
- •Valentine Brousse (MD,PHD,) Florence Missud, Laurent Holvoet, Gislaine Ithier (MDs)
- •Angele Mouopouondo, Valèrie Rigaux (Psychologists)
- •Sylvie Vernois, Kagny Traore, Arouny Kehoavong (Head Nurse and educational as well as coordinating Nurses)
- •Sabrina Lecerf (social worker)
- •Zinedine Haouari (MD data base manager)
- •Celine Vivier (Teacher, N E S)

Radiology unit

Marianne Allison

- •Monique Elmaleh
- •Suzanne Verlhac

Neonatal screening and molecular biology,

- Nathalie Couque
- •Bichr Allaf
- •Rolande Ducrocq
- •Jacques Elion
- •Helene Cave

Epidemiological research unit, ECEVE

- •Corinne Alberti
- •JULIE Sommet
- •Priscilla Boizeau, Enora Le Roux, Damir Mohamed



for rare or low prevalence complex diseases

 Network Hematological Diseases (ERN EuroBloodNet)







All collaborators both on site and of site

French Blood Bank

Emmanuelle Lesprit Anne Arnould France Noizat-Pirenne

Instituts












for rare or low prevalence complex diseases

Network Hematological Diseases (ERN EuroBloodNet)

Thank You Very Much!





Discussion



for rare or low prevalence complex diseases

